Precision BioSciences (NASDAQ:DTIL) reported Q4 EPS of ($0.26), $0.06 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $10.59 million versus the consensus estimate of $6.81 million.
Precision BioSciences (NASDAQ:DTIL) reported Q4 EPS of ($0.26), $0.06 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $10.59 million versus the consensus estimate of $6.81 million.